Article

jdsupra.com on 2019-02-21 20:21

Why Biotech and Pharma Patents Survive IPR

When the America Invents Act of 2011 ushered in a number of new administrative procedures for challenging issued patents, the biotechnology and ...

Related news

Kyle Bass Loses Round 1 of IPR Attack Against Pharma/Biotech Patents jdsupra.com
Dallas , United States
Tribal Immunity Cannot Shield Patents from IPR jdsupra.com
California , United States , Switzerland
New IPR Petitions Filed Against GSK Vaccine Process Patents jdsupra.com
California , United States , Switzerland
Challenges in Filing Successful IPR Petitions for Video Game Patents jdsupra.com
California , United States , Switzerland
Mylan Files Ten Additional IPR Petitions Challenging Sanofi’s Lantus Patents jdsupra.com
California , United States , Switzerland
Collateral Estoppel Applied by District Court Following IPR on Similar Patents jdsupra.com
California , United States , Switzerland
Federal Circuit Holds Tribal Immunity Does Not Bar IPR of Tribe-Owned Patents jdsupra.com
California , United States , Switzerland
States Cannot Claim Sovereign Immunity to Shield Their Patents From IPR jdsupra.com
California , United States , Switzerland
Senate Proposal for Section 101 Reform: Effect on Biotech/Pharma Inventions jdsupra.com
California , United States , Switzerland
Big Pharma under fire over quality, safety, and patents on costly brand drugs jdsupra.com
California , United States , Switzerland
[Event] 11th Pharma & Biotech Patent Litigation - February 26 - 27, 2019 - Radisson Blu Hotel, Amsterdam jdsupra.com
California , United States , Switzerland , Amsterdam
Biosimilar IPR Appeal Updates jdsupra.com
California , United States , Switzerland
Rituximab IPR Updates jdsupra.com
California , United States , Switzerland
Uncharted Waters: Potential Regulatory Impacts of Coronavirus (COVID-19) on Pharma and Biotech Industries jdsupra.com
California , United States , Switzerland
PanOptis’ Recent Victory against Huawei Demonstrates Why an International Enforcement Approach Is Advisable for Standard-Essential Patents jdsupra.com
California , United States , Switzerland
Aragen Bioscience Files Three Petitions for IPR on Cell-Line Patents jdsupra.com
California , Jilin , Hakko , Kyowa-cho
Fractional Patents jdsupra.com
California , United States , Switzerland
Reexamination Stayed Pending IPR jdsupra.com
California , United States , Switzerland
IPR Estoppel Strikes Again jdsupra.com
California , United States , Switzerland
Looking to 2019 and beyond - accessing the U.S. pharma/biotech market: Considerations for structuring and bridging the valuation gap in life sciences M&A transactions jdsupra.com
California , United States , Switzerland